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Abstract
Background: Osteoporosis is a bone disorder associated with loss of bone mineral density and micro architecture. A balance
of osteoblasts and osteoclasts activities maintains bone homeostasis. Increased bone loss due to increased osteoclast and
decreased osteoblast activities is considered as an underlying cause of osteoporosis.
Methods and Findings: The cures for osteoporosis are limited, consequently the potential of CD34+ cell therapies is
currently being considered. We developed a nanofiber-based expansion technology to obtain adequate numbers of CD34
+
cells isolated from human umbilical cord blood, for therapeutic applications. Herein, we show that CD34
+ cells could be
differentiated into osteoblastic lineage, in vitro. Systemically delivered CD34
+ cells home to the bone marrow and
significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice. The
elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-1 in serum parallel the improvements in bone
micro-architecture. Furthermore, CD34
+ cells improved osteoblast activity and concurrently impaired osteoclast
differentiation, maturation and functionality.
Conclusions: These findings demonstrate a novel approach utilizing nanofiber-expanded CD34
+ cells as a therapeutic
application for the treatment of osteoporosis.
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Introduction
Osteoporosis is a systemic bone disorder, affecting more than
200 million people worldwide [1]. Bone is a dynamic organ that
undergoes constant remodeling via cycles of bone formation and
resorption, by osteoblasts and osteoclasts [2]. Imbalance of
osteoclastic and/or osteoblastic activities generally results in low
bone mineral density (BMD), loss of bone mass and mechanical
strength, leading to increased risk of fractures, typical of
osteoporosis [3]. Impaired osteoblastic differentiation of bone
marrow progenitor cells may also play a significant role in
developing osteoporosis. Age, endocrine malfunction or deficiency,
nutrition, or lack of physical activity, all can imbalance the
osteoblasts and osteoclasts activities, affecting both trabecular and
cortical bone at molecular, cellular and structural levels [4,5]. It
has been shown that reduction in trabecular bone in osteoporosis
is associated with increased adiposity in bone marrow, which could
be due to transcriptional switch in favor of adipogenesis instead of
osteoblastogenesis of bone marrow precursor cells [6,7].
The mesenchymal progenitor cells in the bone marrow give rise
to osteoblasts under the influence of multiple osteogenic signals
specific for their proliferation and differentiation [8]. Osteoblastic
differentiation is initiated by binding of bone morphogenetic
proteins (BMPs) to their receptors that activate transcription
factors, Runx2 and Osterix, and subsequent expression of
downstream osteoblast specific genes such as alkaline phosphatase,
collagen type 1, osteonectin, osteocalcin and bone sialoprotein
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39365[9,10,11]. BMPs upregulate osteoblastic genes via activation of
Smad1/5/8 signaling molecules and regulate mineralization of
osteoblastic cells via Wnt in an autocrine signaling loop [12].
Runx2 is a potent inhibitor of adipogenesis, and is required for the
differentiation of adipocytes to osteogenic lineage [13]. Addition-
ally, balance of osteoprotegrin (OPG): receptor activator of
nuclear factor kappa-B ligand (RANKL) ratio, osteocalcin and
cytokines such as interleukin (IL)-1 IL-4, IL-6, monocyte
chemotactic protein (MCP)-1 and granulocyte macrophage colony
stimulating factor (GM-CSF) have been shown to regulate the
activities of osteoblastic and osteoclastic cells [14,15].
Although, associated with side effects, anti-resorptive and
anabolic therapies are currently available for osteoporosis [3,16].
Furthermore, these therapies have temporary effects, and the
decrease in fracture incidences in long-term is debatable [17,18].
Recently, much effort has been expended to understand the
therapeutic effectiveness of CD34+ cells in various degenerative
diseases. However, the major hurdles are the unavailability of
sufficient number of biologically functional CD34+ cells and
maintaining their regenerative potential for therapeutic applica-
tions.
We previously reported that human CD133
+/CD34
+ cells could
be expanded in vitro up to 250-fold in a serum-free medium on
aminated poly-ether sulfone (PES) nanofiber coated plates within
10 days, while preserving stem cell phenotype and biological
functionality [19]. These cells are considered biologically superior
as they exhibit better engraftment capabilities, express homing
markers (CXCR4 and LFA-1) towards bone marrow and maintain
their multipotency. This allows them to differentiate into multiple
lineages such as endothelial, and hematopoietic lineages. Here we
show that nanofiber-expanded CD34
+ cells could be differentiated
towards osteoblastic lineage, in vitro. Furthermore, CD34
+ cell
transplantation into an osteoporotic NOD/SCID murine model
augments bone formation rate, bone mineral density and improves
bone micro-architecture. These improvements correlate with the
elevated serum levels of osteocalcin, interleukin (IL)-10 and
granulocyte-macrophage colony stimulating factor (GM-CSF),
and decreased level of monocyte chemotactic protein-1 (MCP-1).
CD34
+ cell transplantation not only improved osteoblast func-
tionality but also concurrently impaired differentiation and
maturation of osteoclasts, thereby reducing osteoclast activity in
osteoporotic mice. The findings demonstrate a novel potential of
nanofiber-expanded CD34
+ cells in reverting osteoporosis.
Results
Differentiation of nanofiber-expanded CD34
+ cells
towards osteoblastic lineage
Our previous studies showed that nanofiber expanded human
umbilical cord blood (hUCB) CD34
+ cells retain multipotency as
evident by their ability to differentiate into endothelial or smooth
muscle cells [19,20]. Here we sought, whether these cells could
also be differentiated towards osteoblastic lineage in vitro. To test
that, CD133
+ cells were isolated from hUCB and expanded on
nanofiber coated plates in serum-free expansion medium with
supplements for 10 days, in vitro [19]. The cell phenotype was
confirmed by the expression of CD34, CD45, CXCR4, LFA-1,
MHC-I & II, CD14, CD11a and absence of CD69, CD117,
CD105 using flowcytometric analyses (data not shown). CD34+
cells were then induced to osteoblastic differentiation in the
presence of ascorbic acid and b-glycerophosphate, in vitro.
Remarkable cellular changes in shape and size were observed
within 7 days and mineralized nodules were apparent at 21 days
in more than 95% of the cells (Figure 1A, upper right panel). The
mineral deposition by induced CD34
+ cells was confirmed by the
presence of calcium in Alizarin red stained cells. CD34
+ cells
cultured in tissue culture media (TCM) lacking ascorbic acid and
b-glycerophosphate, also showed few randomly scattered cells with
faint intracellular alizarin red staining (Figure 1A, lower left panel).
However, the intensity of stain was markedly higher in cells
induced to differentiate into osteoblastic lineages (Figure 1A, lower
right panel).
Molecular evidences for osteoblastic differentiation of
CD34
+ cells
To further investigate the differentiation of CD34
+ cells into
osteoblastic lineage, the expression of osteoblast specific genes and
proteins were analyzed. Semi quantitative RT-PCR analysis
revealed that differentiated nanofiber-expanded cells upregulated
expression of transcription factor Runx2, and bone associated
proteins such as alkaline phosphatase, osteocalcin, osteonectin and
collagen type 1A1 at various time points during the course of
differentiation (Figure 1B). The expression of osteocalcin in freshly
isolated CD133
+ cells was consistent with earlier reports [21]. Fold
increase for the gene expressions at mRNA level compared to
undifferentiated control was analyzed, as follows: Runx2; Day 7,
0.8460.14; Day 21, 1.1860.1; Alk Phos; Day 7, 0.960.05; Day
21, 1.760.13; Osteocalcin; Day 7, 1.0260.05; Day 21, 1.5660.1;
Osteonectin; Day 7, 1.1660.04; Day 21, 1.5160.48; Collagen
1A1; Day 7, 0.6160.13; Day 21, 1.7960.27. Additionally,
immunocytochemical analysis revealed that CD34
+ cells stained
positive with Smad1/5/8 and osteocalcin upto 21 days of
differentiation (Figure 1C). Western blots showed an increase in
protein levels of BMP2, BMP4, dishevelled protein (DVL) 2,
DVL3 and Smad1/5/8 in differentiated cells at all time points
during the course of differentiation. GAPDH was used as loading
control and MC3T3 cells differentiated into osteoblasts were used
as a positive control (Figure 1D). Fold increase of the protein level
compared to undifferentiated control was analyzed, as follows
BMP2; Day 7, 0.7860.24; Day 21, 1.260.01; BMP4; Day 7,
0.4560.2; Day 21, 1.760.61; Smad 1/5/8; Day 7, 1.4660.04;
Day 21, 1.0160.12; DVL2; Day 7, 0.7260.09; Day 21, 1.160.12;
DVL3; Day 7, 1.2460.04; Day 21, 1.060.12. Collectively, these




+ cells induce bone formation
in a murine model of osteoporosis
We further investigated the therapeutic potential of nanofiber-
expanded human CD34
+ in a mouse model of dexamethasone-
induced osteoporosis in immunocompromised NOD/SCID mice.
Mice (n=6/group) injected with dexamethasone for 21 consec-
utive days, followed by withdrawal for 5 days with tapering dose,
and subsequently were either not treated and sacrificed (Op),
treated with CD34
+ cells via intra-cardio-ventricular injection
(Op+ Cells; 0.5610
6/mouse), or treated with DMEM alone
(Op+Med). Mice in all groups did not exhibit weight loss or gain
during the course of experimentation. Hematoxylin and eosin (H
& E) staining of longitudinal sections of femurs showed a decrease
in the number of trabecular bone spicules in Op and Op+Med
mice, as compared to untreated controls. However, after 28 days
of CD34
+ cell transplantation, an increase in the numbers of
trabecular bone spicules was observed (Figure 2B, arrows). The
number of adipocytes was significantly increased in Op and
Op+Med mice, as compared to untreated control (Figure 2B,
arrowheads). Further, the number of adipocytes was evaluated in
each group and a marked reduction in adipocytes was observed in
CD34
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adipocytes/high power field (HPF) was: control, 9.562.7; Op,
34.2567.5; Op+Media, 29.7563.9; Op+Cells, 13.7561.7
(Figure 2C, lower panel).
CD34
+ cells home to the bone marrow
The chemokine receptor, CXCR4 binds to SDF-1, a chemo-
tactic ligand expressed by bone marrow cells. Additionally, the
presence of lymphocyte adhesion molecules (LFA-1) is required for
the bone marrow homing of CD34
+ cells. Since, we observed that
both CXCR4 and LFA1 are highly expressed on CD34
+ cells after
10 day of expansion on nanofibers, we next sought to examine the
homing of these cells in the osteoporotic mice. Although delivered
systemically, via intra-cardio-ventricular injection, CD34
+ cells
home to bone marrow (Figure 2D) as well as other organs such as
lung, liver and spleen (data not shown). In the bone marrow,
CD34
+ were detected near the endosteal sites and around the bone
marrow sinusoids, as well as at the surface of trabecular bone
Figure 1. Osteoblastic differentiation of nanofiber-expanded CD34
+ cells. (A). Morphology of the cells was visualized under phase contrast
microscope at day 1 (control, upper panel) after seeding of nanofiber-expanded CD34
+ cells (10 days expansion of CD133
+/CD34
+ cells on nanofiber)
and at day 14 after differentiation of cells with osteoblast specific stimulants (b-glycerophosphate and ascorbic acid) in DMEM complete medium
cultured on a 24-well tissue culture plate. Arrowheads indicate the clusters that formed after differentiation. Alizarin Red S staining (lower panel) was
performed to the cells cultured for 21 days either with osteoblast specific differentiation medium (differentiated cells) or DMEM complete medium
only (control). Red stains in the control image indicate the intracellular calcium in random differentiated cells and arrowheads indicate higher level of
mineral depositions in differentiated cells. The experiment was repeated at least three times and representative images are shown. (B). RNA was
isolated from differentiated cells during the course of osteoblastic differentiation at various time points as stated, and one microgram of RNA was
used to make cDNA. One micro liter of cDNA was used to perform semi-quantitative RT-PCR analysis for Runx2, alkaline (Alk) phosphate, osteocalcin,
osteonectin, collagen Type 1A1 and GAPDH as a loading control. Nanofiber expanded cells (10 days) were used as a control. (C). Detection of
osteoblast specific proteins in differentiated cells. Immunocytochemical staining was performed with the 21 days-differentiated cells using either
Sma and Mad related proteins (Smad 1/5/8) or osteocalcin specific antibodies, and IgG isotype as control. Green fluorescence indicates positive
staining and blue fluorescence indicate DAPI (nuclear) staining. (D). Protein levels were evaluated for various signaling molecules of BMP, Wnt and
Smad pathways during the course of osteoblastic differentiation of nanofiber-expanded CD34+ cells. Undifferentiated nanofiber-expanded cells and
differentiated MC3T3 cell line were used as controls. Representative of three sets of experiments is shown here.
doi:10.1371/journal.pone.0039365.g001
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after 2 weeks (Figure 2D, upper right panel).
Mineral apposition rate in response to CD34
+ cell
transplantation
To determine the effect of CD34
+cell transplantation on the
mineral apposition rate (MAR), calcium binding fluorescent dye
calcein (green) was injected at 17 days post CD34+ cell or medium
injection. Subsequently, on day 24, fluorescent dye alizarin (red),
and femurs were harvested on day 28. The inter-label distance
between the two dyes was narrower at cortical and trabecular
regions of the Op+Med mice compared to the Op+Cells mice
indicating limited bone deposition in Op+Med mice. The values
for mineral apposition rate were assessed in plastic embedded
femur bone sections of Op+Med and Op+ Cells on the endosteal
surface of metaphysial region of the femur, distal to the growth
plate (Cortical MAR, mm/day; Op+Med, 0.4760.04; Op+Cells,
3.0760.29). Similarly, significant increase in trabecular MAR was
observed in Op+Cells compared to Op+Med at the growth plate
region (Trabecular MAR, mmm/day; Op+Med, 0.4960.05;
Op+Cells, 1.3560.09) (Figure 3).
Ultra structural analysis of bones after CD34
+cell
transplantation
To evaluate the extent of trabecular and cortical bone repair/
regeneration and to image the differences in bone quality at the
ultrastructural level, femurs from Op, Op+Med, Op+Cells were
examined by micro computed tomography (MicroCT) (Figure 4A–
1B, left panels). Quantitative analyses showed an increase in
trabecular number in Op+Cells as compared to Op+Med mice
(trabecular number, 1/mm; control, 0.4660.1; Op, 0.1160.1;
Op+Med, 0.2360.1; Op+Cells, 0.6460.1) (Figure 4A, upper right
Figure 2. Effect of CD34
+ cells on bone histomorphology in femurs of osteoporotic NOD/SCID mice. Osteoporosis (Op) was developed
by injection of dexamethasone (for 21 days and 5 days for withdrawal) or saline as a control (Control) in seven month-old female NOD/SCID mice.
Nanofiber-expanded CD34
+ cells (half a million per mouse) were injected to the osteoporotic mice (Op+Cells) and serum-free medium was used as a
media control (Op+Med). Femurs were harvested after 28 days of CD34+ cell injection, fixed, embed and H & E staining was performed. (A). An
increased number of cortical bone micro fissures (arrowheads) were found in Op mice compared to control and numbers were reduced in Op+Cells
animals. (B). A decreased number of trabecular bone spicules (arrows) and increased numbers of adipocytes (arrowheads) were found in Op mice
compare to control under the growth plate region. In Op+Cells animals increased number of trabecular bone spicules and a decreased number of
adipocyes were observed (n=6/each group). (C). Evaluated numbers of microfissures and adipocytes per high-power field (HPF) in femur bone
sections were shown in a graphical form (n=6, four HPF/section). (D). Detection of systemically delivered GFP+ nanofiber-expanded human CD34
+
cell in the bone marrow after 48 h and two weeks. Arrows indicate trabecular bone and sinusoids within the bone marrow.
doi:10.1371/journal.pone.0039365.g002
CD34
+ Cells Reverse Osteoporosis
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39365panel). Similar trend was observed for trabecular thickness (mm):
control, 0.6360.06; Op, 0.4560.02; Op+Med, 0.4660.09;
Op+Cells, 0.5960.04. A significant increase in trabecular bone
volume/ total volume was observed in Op+Cells mice, as
compared to Op+Med mice, i.e., trabecular bone volume/total
volume in control, 4.6761.5; Op, 0.5560.4; Op+Med, 1.5961.1;
Op+Cells, 10.2263.8 (Figure 4A, lower right, panel). Similarly,
similar pattern was observed for bone mineral density (BMD) of
the trabeculae. BMD was significantly increased in Op+Cells mice
compared to Op +Med (BMD, g/cm
3; control, 0.22360.02; Op,
0.12160.02; Op+Med, 0.12960.02; Op+Cells, 0.2160.01). The
reductions in BMD in Op mice indicated that dexamethasone
treatments effectively decreased mineral density, and BMD was
increased after CD34
+ cell transplantation indicated reversal of the
osteoporotic phenotype. Similarly, significant decrease in the
degree of anisotropy (DA) was observed in the Op+Cells mice
compared to Op+ Med mice (DA; control, 2.260.29; Op,
360.28; Op+Med, 2.660.23; Op+Cells, 1.7560.1). Our data
correlates with the previously reported results where higher degree
of anisotropy was observed in osteoporotic bone compared to their
healthy controls [22,23]. Similarly, structure model index (SMI) of
the trabeculae bone was reported to be an important predictor of
changes in micro-architecture of trabeculae in osteoporotic
conditions. SMI indicates three-dimensional shape of the trabec-
ular bone. Value of SMI for ideal plate is 0 and for ideal rod is 3
[24]. Transition from plate to rod shape has been reported in
osteoporotic and aged bones when compared to the healthy
controls [25]. Similarly, our data showed a transition from more
rod like structures in Op, Op+Med mice and more plate like in
Op+Cells mice (SMI; control, 0.260.22; Op, 1.0 60.017;
Op+Med, 1.1360.25; Op+Cells, 0.2760.08).
Metaphysial bones were also analyzed for cortical porosity, ratio
of total bone volume to tissue volume and bone mineral density
(BMD). MicroCT analysis of cortical bones revealed significant
decrease in BMD in Op+Cells mice as compared to Op+Med
mice, (BMD, g/cm
3; control, 0.2860.02; Op, 0.260.01;
Op+Med, 0.1960.02; Op+Cells, 0.3360.01). Similar results were
obtained for ratio of cortical bone volume/tissue volumes (control,
79.6462.13; Op, 66.460.86; Op+Med, 6761.34; Op+Cells,
77.964), suggesting a marked increase in cortical bone volume/
tissue volume in Op+Cells mice as compared to Op+Med mice.
Furthermore, results for cortical bone revealed a non-significant
decrease in porosity of cortical bones in Op+Cells mice as
compared to Op+Med mice, (cortical bone porosity (%); control,
17.1761.3; Op, 35.5260.5; Op+Med, 29.3564.9; Op+Cells,
25.0361.77) (Figure 4B, upper right panel).
CD34
+ cell transplantation elevated serum levels of
osteocalcin
As osteocalcin is the characteristic marker of osteoblast function,
the levels of osteocalcin in the serum were evaluated to investigate
in vivo effects of CD34+ cell therapy on osteoporotic mice. As
shown in Figure 5, after osteoporosis, the serum levels of
osteocalcin decreased as compared to untreated control mice.
However, after CD34
+cell transplantation, the levels of serum
osteocalcin (ng/ml) were elevated, as follows: control, 30.561.1;
Op, 24.260.04; Op+Med, 27.56 and Op+Cells, 30.7261.7. This
increase in the levels of serum osteocalcin indicates potential
Figure 3. Detection of in vivo bone regeneration. In vivo immunolabeling with calcein (green) and alizarin (red) was performed in osteoporotic
mice that received CD34
+ cell (Op+Cells) or medium (Op+Media) as a control 10 and 3 days respectively before sacrifice of the mice. Femurs were
harvested, formalin fixed and then embedded in methylmethacrylate resin. Thirty mm thick sections were mounted on the slides and observed under
a fluorescence microscope. Increased mineral apposition rate (MAR) was observed in the endosteal sites of the cortical bone as well as trabeculae,
distal from the growth plate, as detected by green fluorescence in mice that received CD34+ cells compared to control (n=3/group). The values of
MAR (mm/day) for the cortical and trabecular bone are shown graphically.
doi:10.1371/journal.pone.0039365.g003
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consequence of CD34
+cell transplantation in Op mice.
Serum levels of cytokines and growth factors
It was reported that in vitro cultures of osteoblasts produce
factors such as granulocyte-macrophage colony stimulating factor
(GM-CSF) and interleukin-1 (IL-1) [26]. Multiplex ELISA was
performed to analyze the levels of serum cytokines and growth
factors implicated to play significant role in bone homeostasis
(from Quansys Biosciences, Logan Utah). Out of 20 markers tested
(n=4 mice/group) four (MCP-1, GM-CSF, and IL-10) showed
marked changes in all groups (Figure 5). CD34
+ cell transplan-
Figure 4. MicroCT images and analyses of bones. Formalin fixed femur bones were scanned using a high resolution MicroCT scanner (SkyScan
1172-D) established at 16 mm resolution and analyzed with the associated software (CTan). (A). Three dimensional image reconstruction of trabecular
bones towards the distal side of the femur and, 0.1 mm away from the metaphyseal side of the growth plate is shown for each group (upper; left
panel) and analysis is shown (upper; right panel) (n=6/group). (B). MicroCT images (lower; left panel) and analyses of cortical bones (lower; right
panel). Three dimensional (3D) image reconstruction of metaphyseal bones were generated at 2 mm away from growth plate and shown in the left
panel. Analyzed data is presented in the lower; right panel (n=6/group). NS= non-significant.
doi:10.1371/journal.pone.0039365.g004
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the osteoporosis. GM-CSF and MCP-1 levels were shown to have
opposite effects on the osteoclast function [14]. Our data revealed
a marked increase in MCP-1 levels in the Op mice while MCP-1
levels plummet after the CD34
+ cell transplantation in Op mice
(MCP-1 in control, 116.7767.1; Op, 156.92612.8; Op+Med,
125.5767.8; Op+Cells, 87.9569.3). Reverse trend was observed
for GM-CSF levels (control, 17.9562.7; Op, 5.661.3; Op+Med,
5.161.5; Op+Cells, 12.2261.7). Interestingly, we observed that
levels of IL-10 (pg/ml) were suppressed in Op and Op+Med mice
but were dramatically upregulated in Op+Cells mice (IL-10 in
control, 2.92560.8; Op, 1.36 0.1; Op+Med, 1.97560.5;
Op+Cells, 12.562.3). As there was a high variation among the
animals and number of animals was small, results were not
statistically significant when posthoc analysis was performed by
using Bonferroni correction.
Impaired osteoclast differentiation following CD34
+ cell
transplantation
Our observations regarding altered levels of cytokines and
growth factors and increased bone formation suggested possible
effects of CD34
+ cell transplantation on differentiation and/or
function of bone resorbing osteoclasts. Thus, we investigated any
changes in differentiation or function of osteoclasts in Op mice
with or without CD34
+ cell transplantation. Bone marrows
harvested from mice from all groups were allowed to adhere to
the plastic overnight in the presence of M-CSF. Non-adherent
cells were then induced to osteoclastic differentiation in the
presence of M-CSF and RANKL. During the course of
differentiation, cells were harvested at various time points (day 3
and 6) and osteoclast specific tartrate resistant acid phosphatase
(TRAP) staining was performed to detect cells differentiating into
mature osteoclasts. Osteoclasts were defined multinucleated
TRAP+ cells. At day 3 and 6, significant numbers of cells were
positive for TRAP staining in Op+Med mice. By day 6, extensive
numbers of large multinucleated cells were positive for TRAP
staining in the osteoporotic animals (Figure 6A, left panel).
However, significantly less numbers of TRAP positive multinu-
clear cells were observed in animals that received CD34
+ cells
(Figure 6A, right panel). Quantification of TRAP+ cells at both
days 3 and 6 is shown graphically (Figure 6A).
Reduced functionality of osteoclasts after CD34
+ cell
transplantation
Osteoclasts use actin rich, ring-shaped attachment structures
called sealing zone instead of focal adhesions for adherence to
mineralized substrate. Generation of the sealing zone is require-
ment for osteoclasts to resorb bone. Therefore, to evaluate the
osteoclast function, cells were immunostained for F-actin ring
formation using anti-F-actin specific antibody. The cells from bone
marrow of Op mice (Op+Med), demonstrated formation of clear
F-actin rings (Figure 6B, upper left panel). Contrarily, clear F-actin
ring in the bone marrow cells from Op+Cells mice was not
observed. We next assessed whether F-actin ring lacking bone
marrow cells from Op+Cells mice could resorb bone, using ivory
slices as substrate. As shown in Figure 6B, lower right panel,
osteoclast-like cells from Op+Med mice resorbed bone as
evidenced by the large pits formed in ivory slices. The number
and size of resorbed pits were significantly reduced in cells from
Op +Cells mice (Figure 6B, lower left panel), indicating that
CD34+ cell therapy significantly reduced osteoclast differentiation
and function (number of pits/ HPF: Op+Med, 15.562.1;
Op+Cells, 4.560.7; and pit area (mm
2)/ HPF: Op+Med,
1420.266329.3; Op+Cells, 164.3619.6).
Figure 5. Serum levels of cytokines and growth factors. Blood was collected from all groups of animals (Control, Op, Op+Med and Op+Cells)
before sacrifice and collected serum was stored at 280uC freezer. Increased levels of serum osteocalcin (indicative of bone formation) were observed
in the mice that received CD34
+ cell. Sandwich ELISA was performed to evaluate serum levels in all groups of animals using an osteoclacin ELISA kit
(Biomedical Technologies, Inc, Staughton, MA), (n=4 in triplicate). To assess the levels of various cytokines and growth factors (twenty factors) from
collected serum (250 ml/animal) the multiplex ELISA was performed in triplicate by Quansys Biosciences, Logan Utah (n=4/group). The values of
MCP-1, GM-CSF and IL-10 were graphically reported as mean 6 SEM.
doi:10.1371/journal.pone.0039365.g005
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Despite the hematopoietic origin of nanofiber expanded CD34
+
cells, herein we show that these cells could be differentiated
towards osteogenic lineage. Both hematopoietic and osteogenic
cells express similar families of transcription factors such as Cbfa/
Runx with some differences in expression levels of their sub family
members [27,28]. These observations led us to believe that hUCB
Figure 6. Impaired osteoclast differentiation, maturation and functionality in osteoporotic mice received CD34
+ cells. Harvested
bone marrow was subjected to differentiation towards osteoclasts using M-CSF and sRANKL (n=5). (A). During the course of differentiation at day 3
and 6, cells were stained with tartrate-resistant acid phosphatase (TRAP). The purple color was considered to indicate TRAP+ cells (arrows, left panel)
and the yellow color as TRAP- cells. Nuclei were stained with DAPI for counting cell numbers. The Op+Med showed an increased number of TRAP+
cells at day 3 (upper, right panel) as well as day 6 compared to Op+Cells (lower, right panel). Evaluated values of differentiated osteoclasts are
graphically presented. (B). To determine osteoclast functionality on day 4 of differentiation, osteoclasts were harvested and plated on thin ivory slices.
Bone resorption assays were performed using osteoclasts from all four groups of animals and to analyze the formation of F-actin rings on ivory bone
slices (arrow, upper; left panel). Ivory slices were stained with hematoxylin and analyzed for the resorbed pits on day 10 of differentiation. The
formation of F-actin rings was assessed by F-actin specific antibody (green fluorescence). F-actin rings were prominent in osteoclasts derived from
Op+Med animals (arrow, upper; left panel), however, osteoclasts derived from Op+Cells animals stained negative for F-actin ring (arrow, upper; right
panel). Fewer and smaller resorption pits formed by osteoclasts from Op+Cells animals (arrow, lower; right panel) compared to those formed by
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+ cells might also have potential to differentiate in
the osteoblastic lineage. Indeed, we have observed that CD34
+
cells in response to osteogenic signals, ascorbic acid and b-
glycerophosphate, expressed Runx2, osteocalcin, osteonectin,
collagen1A1, alkaline phosphatase, and BMP, Smad and Wnt
signaling molecules, which are characteristically expressed by
osteoblasts [29]. Runx2 is required for osteogenic differentiation of
mesenchymal cells, whereas osteocalcin, osteonectin and collagen
type1A1 are integral to bone matrix [9,10,30]. BMPs expressed by
osteoblasts, bind and transduce signals via receptors to activate
Smad 1/5/8 signaling pathway, to induce gene expression for
bone-associated proteins [10]. Wnt signaling associated proteins
Dvl2 and Dvl3 are required to transmit signals during osteoblastic
differentiation [31,32]. These findings provide evidence that
hUCB derived CD34
+ cells are multipotent in nature and
microenvironmental cues could drive their differentiation towards
osteoblastic lineages.
Characteristic hallmark of osteoporosis is the loss of bone. We
have observed that, following dexamethasone treatment mice
exhibit significant decreases in trabecular and cortical BMDs
compared to controls. Trabecular bone micro architectural
parameters such as anisotropy and structure model index also
provide strong evidences that dexamethasone was able to induce
osteoporosis. This bone loss and changes in bone micro-
architecture were almost restored within 28 days following
application of a single bolus of hUCB derived CD34
+ cells. In
osteoporosis, the balance of osteoblast and osteoclast cells is
severely compromised. The number of osteoclasts is increased and
they obliterate bone micro-architecture, which ultimately results in
loss of bone mass [33,34]. This is further accompanied by the bone
marrow stromal cells differentiation towards adipogenesis and
inhibition of osteoblastogenesis [35]. In the current study, we
found the loss of trabecular bone spicules and loss of cortical bones
in the osteoporotic mice and concurrent increment of adipocytes.
However, application of nanofiber-expanded CD34
+ cells induced
significant reversion of osteoporosis, by increment of bone
formation presumably by osteoblasts and concomitant decrease
in number of adipocytes and osteoclasts. In fact, circulating
CD34
+ cells have been shown to be recruited to the skeletal defect
sites and heal non-union fractures in murine models [36,37]. The
chemokine receptor, CXCR4 binds to stromal derived factor
(SDF)-1 expressed highly in bone marrow stromal cells, and is
required for efficient homing of cells to the bone marrow [38].
Since, nanofiber-expanded CD34
+ cells constitutively express high
levels of CXCR4, this may be critical for homing of these cells to
bone marrow. In a preclinical model of osteoporosis, adenoviral-
mediated overexpression of CXCR4 gene was shown to be
necessary for bone marrow derived mesenchymal cells, to home in
the bone marrow [39]. However, advantages of using the
nanofiber-expanded cells are that we do not need to induce
CXCR4 expression using any viral methods, which has potential
to integrate to the host genome [40]. Although nanofiber-
expanded cells home to the other organs such as lung or spleen
besides bone marrow, no bone formation was observed in other
organs. Also, recently it was shown that CXCR4 expression on the
precursor cells was important for bone formation [41]. Addition-
ally, hUCB derived CD34
+ cells have greater advantage in that
these cells have not been reported to induce oncogenic transfor-
mation in experimental model systems [20].
During osteoporosis, osteoblasts undergo apoptosis, thereby,
altering the bone formation and lowering bone mineral density.
This is paralleled by lower levels of serum osteoclacin, a marker for
bone turnover [42]. Current findings show that CD34
+ cell
transplantation decreased the numbers of adipocytes in bone
marrow, increased trabecular numbers and thickness, and
increased BMD, thereby indicating induction of osteoblast in
bone. An increase in the osteocalcin levels coupled with an
increase in vivo mineral apposition rate in the mice that received
CD34
+ cell transplantation, confirms the regenerative potential of
CD34
+ cells in bone formation.
Elevated levels of GM-CSF, and IL-10 and decreased level of
MCP-1 in serum were also evident with the CD34
+ cell
transplantation. Previous in vitro studies have shown that in the
presence of CD34
+ cells, osteoblasts secrete GM-CSF and
cytokines such as IL-6, IL-4 and IL-1 involved in bone homeostasis
[15,43,44]. Current findings suggest that CD34
+ cells likely
modulate cytokine secretions during induction of osteogenesis. In
this respect, we have observed high level of IL-10 in serum of the
mice that received CD34
+ cells. The importance of IL-10 in bone
metabolism was demonstrated in IL-10 deficient mice, which
develop osteopenia and decreased bone formation [45,46]. IL-10
exhibits anti-osteoclastic activity and may directly inhibit osteoclast
precursor cell differentiation [47]. CD34
+ cell transplantation thus
acts by upregulating the levels of IL-10 that may in turn regulate
the bone remodeling by impairing osteoclastogenesis and restoring
the bone formation [46,47].
Above findings thus demonstrate a novel therapeutic potential
of nanofiber-expanded CD34
+ cells in resolving osteoporosis.
These cells provide several advantages over other cell types as they
are easily accessible, less immunogenic and maintain multi-
potency. They can be available in unlimited numbers via
expansion on nanofibers; constitutively express CXCR4 for
efficient homing to the bone marrow; and differentiate into
osteogenic lineage in vitro. These cells are biologically functional as
they significantly improve bone mineral density, bone formation
and bone micro-architecture in osteoporotic murine model. These
characteristics make them an attractive choice of cells for bone




Fresh human umbilical cord blood was obtained from The
Ohio State University Medical Center with written consent from
donors and prior approval from the internal review board. Briefly,
heparinized cord blood was diluted with PBS (1:1) and carefully
layered over 10 ml of Ficoll-Paque (GE Health Care-Biosciences,
USA). After 30-min centrifugation in a swinging bucket rotor at
1400 rpm, the upper layer was aspirated and the mononuclear cell
layer (buffy coat) was collected. Following labeling with magnetic
bead conjugated anti-CD133 monoclonal antibody (Miltenyi
Biotec Inc, Bergisch Gladbach, Germany), two cell separation
cycles (with different columns) were performed using the
AutoMACS cell sorter (Miltenyi Biotec) following manufacturer’s
protocol and reagents. After separation, purity of the cell product
was determined by flow cytometry (more than 95% cells were
CD133
+). Total 4–6 samples of cord blood were procured, isolated




Electrospinning, surface grafting, and amination of PES
nanofibers were carried out according to the procedure described
earlier [48]. All chemicals were purchased from Sigma-Aldrich
(USA) unless otherwise stated. PES granules were purchased from
Goodfellow Cambridge Limited, UK. CD133
+ cells were
expanded on nanofiber-coated plates using serum free expansion
medium (SFEM) as previously described [19]. In brief, purified
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thrombopoietin (TPO), and IL-3 were purchased from Peprotech
Inc. (Rocky Hill, NJ). The StemSpan SFEM medium was
purchased from StemCell Technologies (Vancouver, BC, Cana-
da). Nanofiber meshes were securely glued to the bottoms of wells
of a 24-well tissue culture plate. Eight hundred CD133
+ cells were
seeded onto each scaffold in 0.6 ml StemSpanTM serum-free
expansion medium, which consists of 1% BSA, 0.01 mg/ml
recombinant human insulin, 0.2 mg/ml human transferrin,
0.1 mM 2-mercaptoethanol, and 2 mM L-glutamine in Iscove’s
MDM, supplemented with 0.04 mg/ml low-density lipoprotein
(Athens Research and Technology Inc., USA), 100 ng/ml SCF,
100 ng/ml Flt3, 50 ng/ml TPO, and 20 ng/ml IL-3. Cells were
cultured at 37uC in an atmosphere containing 5% CO2 for
10 days without medium change. Cells were harvested after
10 days of expansion. All wells were washed once with non-
enzymatic cell dissociation solution and twice with 2% FBS
containing Hanks’ buffer at 5 min intervals between each wash.
The collected cells were then concentrated through centrifugation
at 3006g for 5 min. Aliquots of the cells were then used for cell
counting by a hemocytometer, flowcytometric analysis, as well as
for further studies.
Flowcytometry
Flowcytometric analysis was performed by using standard two
colors staining with a FACS Calibur flowcytometer (Becton
Dickinson, Heidelberg, Germany) as described earlier [19]. Non-
specific Fc-receptors were blocked with FcR-blocking reagent
(Miltenyi Biotec Inc.) prior to adding primary antibodies. Primary
antibody was incubated for 30 min at 4uC with the aliquots of
expanded cells. Antibodies used were anti-CD34-PE, anti-
CD133/2-FITC (all from Miltenyi Biotec Inc), PE labeled
CXCR4, von Willebrand Factor, CD31, CD45, MHC class I,
MHC class II, CD69, CD3, Mac-I, LFA-1, CD86, CD14 and
isotype controls were purchased from BD Biosciences (USA) After
incubation cells were washed with MACS buffer and resuspended
in MACS buffer. Dead cells were excluded via propidium iodide
staining. Data analysis was performed with BD Cell Quest
software. The Milan-Mulhouse gating method was used for cell
enumeration, where a double gating (CD133
+ and CD34
+)
strategy was used to identify the primitive hematopoietic
progenitor cell populations. At least 20,000 events were acquired.
Osteoblastic differentiation of nanofiber-expanded
CD34
+ cells
After 10 days of CD133
+ cell expansion on nanofiber, cells were
collected and reseeded in DMEM supplemented with 10% fetal
bovine serum (FBS), penicillin, streptomycin, and glutamate (PSG)
for three days in a 24-well plate or 4-chamber slides (Lab-Tek II
Chamber slide System, Nalge Nunc International Corp., Naper-
ville, IL, USA). The cultured cells were induced by specific
osteoblast differentiating factors (60 mM ascorbic acid and 10 mM
b-glycerophosphate) dissolved in fresh DMEM complete medium.
The differentiation process was continued for 3 weeks with a
change of fresh medium containing specific osteoblast inducing
factors in every 3rd day. During the process of differentiation,
some of the wells of differentiated cells were harvested at specific
time points for further studies (n=4).
Alizarin red S staining
To examine in vitro mineralization in osteoblastic differentiated
cells, Alizarin Red S staining was performed in wells of a 24-well
plate. Briefly, after 21 days of differentiation cells were fixed in
70% ethanol for one hour at room temperature followed by a wash
with water (10 minutes, 2 times) and incubated with 1% Alizarin
Red S solution for 30 minutes at room temperature (Chemicon
International, USA). The red stain was washed with water three
times and cells were mounted with mounting solution. Images
were obtained by using a digital camera attached to the
microscope (Axioplan2; Carl Zeiss) using Axio-vision software
(Carl Zeiss, NY, USA). Nanofiber-expanded CD34
+ cells cultured
in DMEM complete medium were used as a control.
Immunocytochemical staining
One quarter of a million nanofiber-expanded CD34
+ cells were
induced to differentiate in each well of 4-chamber slides for three
weeks. After three weeks of culture immunocytochemistry was
performed following standard protocol to assess osteoblastic
differentiation using osteoblast specific markers such as Smad 1/
5/8, osteocalcin and IgG as an isotype control. Nuclear stain was
performed with DAPI. Slides were observed under a fluorescence
microscope (Axioplan2; Carl Zeiss) and images were captured with
Zeiss Axiovision imaging software (Carl Zeiss, NY, USA).
RT-PCR and western blot analyses
Nanofiber-expanded CD34
+ cells were induced to osteoblastic
differentiation in vitro. During the course of osteoblastic differen-
tiation, total RNA and proteins were isolated at various time
points using RNeasy Kit (Qiagen, USA) and RIPA, cell lysis buffer
respectively. One microgram of RNA was used for cDNA
synthesis using oligo dT (Invitrogen, USA) primer. Semi quanti-
tative PCR was performed using one micro liter of cDNA for the
gene specific primers such as Runx2, alkaline phosphatase,
osteocalcin, osteonectin, collagen 1A1 and GAPDH. Fold increase
for expression of each gene at mRNA level was analyzed using
UN-SCAN-IT software (Silk Scientific, Inc.). Nanofiber-expanded
cells were used as a control. Primers for RT-PCR reactions were
designed using Primer Blast-NCBI software: Human Runx2
forward primer: 59 TAAGTACACGGGCTTCAGGG 39; Hu-
man Runx2 reverse primer: 59 TTGTTGTCTTCTTGCCTCCA
39; Human Alk Phos forward primer: 59 GGACATGCAGTAC-
GAGCTGA 39; Human Alk Phos reverse primer: 59 CAC-
CAAATGTGAAGACGTGG 39; Human osteocalcin forward
primer:59 AAGCAAGTAGCGCCAATCT 39; Human osteocal-
cin reverse primer: 59 GGAAGTAGGGTGCCATAACAC 39;
Human osteonectin forward primer:59 ACATCGGGCCTTG-
CAAATACA 39; Human osteonectin reverse primer: 59 GAAG-
CAGCCGGCCCACTCATC 39; Human collagen1A1 forward
primer:59 CCTGGCCCCATTGGTAATGTT 39; Human col-
lagen1A1 reverse primer: 59 CCCCCTCACGTCCAGATTCAC
39; Human GAPDH forward primer: 59 CTGATGCCCC-
CATGTTCGTC 39; Human GAPDH reverse primer: 59
CACCCTGTTGCTGTAGCCAAATTCG 39.
Similarly, Western blot was performed for the level of BMP2,
BMP4, Smad-1/5/8 (all from Santa Cruz Biotechnology, Inc.,
CA), Dvl2, Dvl3, and GAPDH (all from Cell Signaling Technol-
ogy, Inc. MA) protein. Nanofiber-expanded cells were used as a
control. Induced differentiated MC3T3 cells were also used as a
positive control. Fold increase for expression of each gene at
protein level was analyzed using UN-SCAN-IT software (Silk
Scientific, Inc.).
Generation of osteoporosis
Seven month-old female NOD/SCID mice, retired breeder
(body weight approximately 25 g) were obtained from Jackson
Laboratory, Bar Harbor, ME and used for osteoporosis induction.
The mice were housed in sterile IACUC-approved facilities at the
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week of acclimatization, mice were intraperitoneally (i.p.) injected
with 5 mg/ kg body weight (b. wt.) of dexamethasone (American
Regent, Inc. Shirley, NY) or with saline (as a control) for
consecutive 21 days as described before [35]. Tapering doses of
dexamethasone were given for 5 days for withdrawal. The mice
were weighed every week during the injection to record any
significant weight loss.
CD34+ cell transplantation
The mice, that received glucocorticoid injections were either
sacrificed after 26 (21+5) days as an osteoporotic control or were
used for CD34+ cell / medium injections (6 mice/group). The
osteoporotic mice were anesthetized and injected with nanofiber-
expanded CD34+ cells (0.5 million in 300 ml of serum free
medium) via intra-cardio-ventricular injection or 300 ml of serum
free medium (Op+Med) as a control for CD34+ cell therapy
group. The osteoporotic mice of CD34+ cell therapy (Op+Cells)
group received only one dose of CD34+ cells and were sacrificed
after 28 days of injection. Osteoporotic mice receiving medium
(Op+Med) were also sacrificed at the same time point.
CD34
+ cell homing
To assess the homing of CD34+ cells, GFP overexpressed
nanofiber-expanded CD34
+ cells (0.5 million cells/mouse) were
injected into the mice via intra-cardio-ventricular injection after
induction of osteoporosis. Forty-eight hours and two weeks after
cell injection, mice were sacrificed and various organs were
harvested. Tissues were fixed in 10% formalin solution and
subsequently embedded in paraffin block. Five-micron sections
were cut and stained using anti-GFP primary antibody (Zymed
Laboratories, Inc, CA, USA) and detected with 3,39-Diamino-
benzidine (DAB) and mounted. Slides were observed under a
microscope (Axioplan2; Carl Zeiss) and images were captured with
Zeiss, Axiovision imaging software (Carl Zeiss).
Mineral apposition rate (MAR)
A separate set of seven months old NOD/ SCID mice (3 mice /
group) were subjected to generation of osteoporosis (21+5 days)
and followed by CD34
+ cell transplantation or medium (as a
control) for 28 days as described above. Mice were intraperitone-
ally (i.p.) injected with calcium binding dye, calcein (green
flourescent dye; 10 mg/kg b.wt., Sigma); 10 days prior to sacrifice.
Alizarin Red Dye (red fluorescent dye; 50 mg/kg b.wt., Sigma)
was also injected to the same mice via i.p. route three days prior to
sacrifice. Upon sacrifice, femurs were harvested and formalin fixed
for 24 hours and then washed with 1x PBS, dehydrated with 70%
ethanol, 95% ethanol, 100% ethanol, infiltrated and embedded in
methylmethacrylate and polyester resin. Thirty-micrometer thick
sections were cut with a diamond blade using Saw Microtome
Leica SP1600 (Leica Microsystem, Wetzlar, Germany). The
sections were mounted on the slides using Vecta Mount (Vector
Labs, Inc. Burlingame, CA) and observed under a fluorescence
microscope (Carl Zeiss, NY, USA) and images were captured with
Zeiss Axiovision imaging software (Axioplan2). Images were
analyzed to assess the mineral apposition rate (MAR) by using
NIH Image J software. The mineral apposition rate (MAR, in mm
per day) was determined by dividing the mean width of the double
labels by the inter-label time as described previously [49].
Hematoxylin and eosin staining
All mice were euthanized after collecting blood and urine, and
femurs were removed by surgical dissection and were preserved in
10% neutral buffered formalin. After decalcification, paraffin-
blocked tissues were sectioned and stained with standard
hematoxylin and eosin (H&E) staining protocol at the same depth
from the growth plate.
Micro computed tomography (MicroCT)
Formalin fixed femur bones were encased in a tight fitted plastic
tube to prevent any motion during scanning. Femurs were scanned
using a high-resolution Micro CT scanner (SkyScan1172-D,
Kontich, Belgium) at 16mm resolution. For measurements of bone
mineral density (BMD; g/cm
3), phantoms of 25 and 75 g/cm
3
were scanned with the same settings as applied to the mice femur
bones from all groups. The scanned images were reconstructed
using Skyscan Nrecon software and analyzed with the CTan
software (Kontich, Belgium). Analyses of trabecular bone were
carried out in distal femur, 0.1 mm away from the growth plate. A
threshold was established and the same threshold value was kept
constant for all samples. Similarly, the metaphysial region, 2mm
away from the growth plate, was selected for the cortical bone
analysis. A separate threshold was established and kept constant
for all cortical bone measurements. The analyses were performed
for the bone volume, bone to tissue volume ratios, trabecular
number (Tb.N; 1/mm), trabecular thickness (Tb.Th; mm),
trabecular bone mineral density (BMD; g/cm
3), degree of
anisotropy (DA), structure model index (SMI), cortical porosities
(%), ratio of bone volume/ tissue volume (BV/TV) and cortical
bone mineral density (BMD; g/cm
3) in animals from all groups
using the Skyscan software and following manufacturer’s protocol.
The results were reported in mean 6 SEM (n=6/ per group).
Three-dimensional (3D) models were reconstructed using CTvol
software from SkyScan.
Serum osteocalcin assay
Sandwich ELISA was performed for the collected mouse serum
using the osteocalcin ELISA kit (Biomedical Technologies, Inc,
Staughton, MA). Briefly, the mouse was anesthetized and blood
was collected from the descending aorta in an eppendorf tube and
kept at room temperature for an hour to coagulate, then
centrifuged at 14000 rpm for 20 minutes at 4uC. Serum was
collected and stored at 280uC until further use. Standard curve
was made and the serum samples were run in triplicates to assess
the amount of osteocalcin in the serum. The samples from each
group were diluted (5x) and incubated with the anti-serum
osteocalcin overnight and detected using streptavidin-horseradish
peroxidase (HRP) detecting system. The values were reported in
mean 6 SEM (n=4/ per group, in triplicate).
Multiplex ELISA for cytokines and growth factors
To assess the levels of various cytokines and growth factors
(twenty factors from 250 ml of serum) from collected serum (from
all groups of animals before sacrifice and stored at 280uC), the
multiplex ELISA was performed in triplicate by Quansys
Biosciences, Logan Utah (n=4/ per group). The values were
reported in mean 6 SEM.
Osteoclast differentiation
To assess the therapeutic effects of CD34
+ cells on the bone
resorbing cells; bone marrow cells were collected from femurs of
animals of all the groups, after termination of experiments and
were induced for osteoclastic differentiation in vitro. Cells were
cultured overnight at 37uC incubator with 5% CO2 in aMEM
containing 10% heat inactivated fetal bovine serum in the
presence of 20 ng/ml M-CSF (R & D Systems, Minneapolis,
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(1.5 million for all the groups) were collected and incubated for
an additional 5–8 days in aMEM medium with 20 ng/ml M-CSF,
and 50 ng/ml GST-RANKL [50]. The fresh medium was
replaced every third day. At day 3 and 6 of differentiation, the
cells were stained for TRAP staining using an acid phosphatase,
leukocyte; TRAP staining kit (Sigma Aldrich, USA) and was
viewed and imaged with a fluorescence microscope (Carl Zeiss,
NY, USA). TRAP-positive cells (purple) containing at least three
nuclei were counted as osteoclasts.
Osteoclast cytoskeleton structure and functionality
Osteoclasts were generated on plastic dishes as described above
and on 3
rd day of differentiation, osteoclasts cells were removed
and equal number of osteoclasts cells were re-plated either on
thinly cut ivory slices or glass cover slips. Cells were fixed at
various time points of culture with 1% formaldehyde in pH 6.5
(30 minutes at room temp), stabilization buffer (127 mM NaCl,
5 mM KCl, 1.1 mM NaH2PO4, 0.4 mM KH2PO4,2 m M
MgCl2, 5.5 mM glucose, 1 mM EGTA, 20 mM Pipes), and
subsequently fixed and permeabilized with 2% formaldehyde,
0.2% Triton X-100, and 0.5% deoxycholate in the same
stabilization buffer. Cells were stained with F-actin specific Ab
and visualized using a Zeiss 510 META laser scanning confocal
microscope (Campus Microscopy and Imaging Facility, The Ohio
State University). Actin ring and podosome thicknesses were
determined by generating Z-stack images of randomly selected
cells and these structures were measured at their thickest points
[50]. Bone resorption was assessed using ivory slices and
osteoclasts were gently removed with cotton swabs and washed
with water. The ivory slices were then stained with hematoxylin
stain for 5 minutes at room temperature and excess stain was
removed by washing with water and pits were imaged with a
confocal microscope mentioned above.
Statistical analysis
Values were expressed as mean 6 SEM and statistical analysis
was performed by using JMP software (version 9, SAS Institute
Inc. NC). After checking equal variance two sample ‘t’-test was
performed for assessment of significance. Posthoc analysis was
performed by using Bonferroni correction and significance was
determined when p values were obtained less than 0.025.
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